Moderna, Inc. (MRNA) shares surged 10.9% in the latest trading session, closing at $35.66, driven by strong trading volume. This increase reflects a total gain of 15% over the past month.
Bank of America Securities recently raised its price target for Moderna from $21 to $24 while maintaining an Underperform rating, anticipating continued influence from COVID-19 vaccine uptake. The company is projected to report a quarterly loss of $2.79 per share, a decline of 11.6% year-over-year, with expected revenues of $683.27 million, down 29.3%. The consensus EPS estimate has seen a 5.8% increase over the past month, indicating potential price appreciation.
Moderna currently holds a Zacks Rank of #3 (Hold) in the Medical – Biomedical and Genetics industry.
